|
1
|
Salama JK, Hasselle MD, Chmura SJ, Malik
R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen
EE, et al: Stereotactic body radiotherapy for multisite
extracranial oligometastases: Final report of a dose escalation
trial in patients with 1 to 5 sites of metastatic disease. Cancer.
118:2962–2970. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Postow MA, Callahan MK, Barker CA, Yamada
Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al:
Immunologic correlates of the abscopal effect in a patient with
melanoma. N Engl J Med. 366:925–931. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Twyman-Saints Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck
M, Sung M, Schwartz M, Divino CM, Pan PY and Chen SH: The novel
role of tyrosine kinase inhibitor in the reversal of immune
suppression and modulation of tumor microenvironment for
immune-based cancer therapies. Cancer Res. 69:2514–2522. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karaman MW, Herrgard S, Treiber DK,
Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI,
Edeen PT, et al: A quantitative analysis of kinase inhibitor
selectivity. Nat Biotechnol. 26:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Faivre S, Demetri G, Sargent W and Raymond
E: Molecular basis for sunitinib efficacy and future clinical
development. Nat Rev Drug Discov. 6:734–745. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ko JS, Zea AH, Rini BI, Ireland JL, Elson
P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al:
Sunitinib mediates reversal of myeloid-derived suppressor cell
accumulation in renal cell carcinoma patients. Clin Cancer Res.
15:2148–2157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schueneman AJ, Himmelfarb E, Geng L, Tan
J, Donnelly E, Mendel D, McMahon G and Hallahan DE: SU11248
maintenance therapy prevents tumor regrowth after fractionated
irradiation of murine tumor models. Cancer Res. 63:4009–4016.
2003.PubMed/NCBI
|
|
10
|
Kao J, Packer S, Vu HL, Schwartz ME, Sung
MW, Stock RG, Lo YC, Huang D, Chen SH and Cesaretti JA: Phase 1
study of concurrent sunitinib and image-guided radiotherapy
followed by maintenance sunitinib for patients with
oligometastases: Acute toxicity and preliminary response. Cancer.
115:3571–3580. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tong CC, Ko EC, Sung MW, Cesaretti JA,
Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, et
al: Phase II trial of concurrent sunitinib and image-guided
radiotherapy for oligometastases. PLoS One. 7:e369792012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kao J, Chen CT, Tong CC, Packer SH,
Schwartz M, Chen SH and Sung MW: Concurrent sunitinib and
stereotactic body radiotherapy for patients with oligometastases:
Final report of a prospective clinical trial. Target Oncol.
9:145–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen HM, Ma G, Gildener-Leapman N,
Eisenstein S, Coakley BA, Ozao J, Mandeli J, Divino C, Schwartz M,
Sung M, et al: Myeloid derived suppressor cells as an immune
parameter in patients with concurrent sunitinib and stereotactic
body radiotherapy. Clin Cancer Res. 21:4073–4085. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chin-Yee IH, Keeney M, Johnson K, Brown W,
Wolfe N and Kaplan S: White blood cell flagging rates of the
Coulter LH 750 analyzer compared with the Coulter Gen.s Hematology
Analyzer. Laboratory Hematology. 7:211–216. 2001.
|
|
15
|
Ellis RE: The distribution of active bone
marrow in the adult. Phys Med Biol. 5:255–258. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu AX, Duda DG, Ancukiewicz M, di Tomaso
E, Clark JW, Miksad R, Fuchs CS, Ryan DP and Jain RK: Exploratory
analysis of early toxicity of sunitinib in advanced hepatocellular
carcinoma patients: Kinetics and potential biomarker value. Clin
Cancer Res. 17:918–927. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gonzalez-Garcia I, Solé RV and Costa J:
Metapopulation dynamics and spatial heterogeneity in cancer. Proc
Natl Acad Sci USA. 99:13085–13089. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tannock IF: Conventional cancer therapy:
Promise broken or promise delayed? Lancet. 351(Suppl 2): SII9–SI16.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morabito A, De Maio E, Di Maio M, Normanno
N and Perrone F: Tyrosine kinase inhibitors of vascular endothelial
growth factor receptors in clinical trials: Current status and
future directions. Oncologist. 11:753–764. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Norden-Zfoni A, Desai J, Manola J, Beaudry
P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, et al:
Blood-based biomarkers of SU11248 activity and clinical outcome in
patients with metastatic imatinib-resistant gastrointestinal
stromal tumor. Clin Cancer Res. 13:2643–2650. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rini BI, Choueiri TK, Elson P, Khasawneh
MK, Cotta C, Unnithan J, Wood L, Mekhail T, Garcia J, Dreicer R and
Bukowski RM: Sunitinib-induced macrocytosis in patients with
metastatic renal cell carcinoma. Cancer. 113:1309–1314. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Cruijsen H, van der Veldt AA, Vroling
L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB,
van den Eertwegh AJ, Boven E, et al: Sunitinib-induced myeloid
lineage redistribution in renal cell cancer patients: CD1c+
dendritic cell frequency predicts progression-free survival. Clin
Cancer Res. 14:5884–5892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Formenti SC and Demaria S: Combining
radiotherapy and cancer immunotherapy: A paradigm shift. J Natl
Cancer Inst. 105:256–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mac Manus M, Lamborn K, Khan W, Varghese
A, Graef L and Knox S: Radiotherapy-associated neutropenia and
thrombocytopenia: Analysis of risk factors and development of a
predictive model. Blood. 89:2303–2310. 1997.PubMed/NCBI
|
|
28
|
Leighl NB: Sunitinib: The next advance in
small-cell lung cancer? J Clin Oncol. 33:1637–1639. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zurita AJ, Khajavi M, Wu HK, Tye L, Huang
X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, et al:
Circulating cytokines and monocyte subpopulations as biomarkers of
outcome and biological activity in sunitinib-treated patients with
advanced neuroendocrine tumours. Br J Cancer. 112:1199–1205. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ko JS, Rayman P, Ireland J, Swaidani S, Li
G, Bunting KD, Rini B, Finke JH and Cohen PA: Direct and
differential suppression of myeloid-derived suppressor cell subsets
by sunitinib is compartmentally constrained. Cancer Res.
70:3526–3536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gilbert MR, Dignam JJ, Armstrong TS, Wefel
JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S,
Won M, et al: A randomized trial of bevacizumab for newly diagnosed
glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kwon ED, Drake CG, Scher HI, Fizazi K,
Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R,
Mahammedi H, et al: Ipilimumab versus placebo after radiotherapy in
patients with metastatic castration-resistant prostate cancer that
had progressed after docetaxel chemotherapy (CA184-043): A
multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol.
15:700–712. 2014. View Article : Google Scholar : PubMed/NCBI
|
